Trial results

Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus

NCT02284009 on ClinicalTrials.gov · last registry update 2020-06-29

Finished 18 October 2017, after enrolling 67 people. albiglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P2

Drug

albiglutide

Tanzeum

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Enrollment

67

Started

2014-10-10

Primary completion

2017-10-18 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52

Conditions studied

Diabetes Mellitus, Type 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the albiglutide page for this molecule’s full trial and approval history.